FDA Plays Musical Chairs In Commissioner's Office: Hot Seat Remains Open
This article was originally published in The Gray Sheet
Executive Summary
The appointment of former FDA Office of Review Management Director Murray Lumpkin, MD, as acting deputy commissioner is part of an Office of the Commissioner restructuring plan announced Oct. 1.
You may also be interested in...
FDA Commissioner Pick OK With Kennedy, Thompson Says; Bush Nod Awaited
Virginia Tech Center for Food & Nutrition Policy Director Lester Crawford, DVM/PhD, may represent the Bush administration's last chance to get an FDA commissioner nominated this year.
Sen. Kennedy Warns Against Picking FDA Commissioner From Industry
The key attributes for the next FDA commissioner from Sen. Edward Kennedy's point of view appear to lend support to the candidacy of Harvard Medical School dermatology lecturer Lynn Drake, MD.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”